ENHERTU, a HER2 directed a DXd antibody drug conjugate (ADC), was discovered by Daiichi Sankyo and is being jointly developed and commercialised by Daiichi Sankyo with AstraZeneca. The
This move comes as part of the research collaboration agreement initiated on 21 December 2021. As per the 2021 deal, Aarvik carried out the discovery and preclinical development
The vaccine candidate is a virus-like particle (VLP)-based, adjuvanted vaccine designed for active immunisation against chikungunya virus (CHIKV) infection. This expedited review process is a significant step towards
The collaboration between Persist AI and Nivagen will leverage AI-based formulation technology of Persist alongside Nivagen’s manufacturing prowess. The goal is to streamline and expedite the development and
Enzeevu is designed to improve and maintain visual acuity in patients suffering from nAMD, a condition that is a primary cause of vision impairment among individuals over 50
BARDA is a part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services. The product, which represents $139.7m of the
Zurnai is indicated for treating suspected or known opioid overdose in adults and pediatric patients aged 12 years and older. It is not a substitute for emergency medical
One indication is for treating adults with priorly treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pancreatic neuroendocrine tumours (pNET). Other one is for use in adults
The territories include Japan, South Korea, and several Southeast Asian countries, including Vietnam, Thailand, Malaysia, the Philippines, Singapore, and Indonesia. CBT-001 is an investigational emulsified nintedanib ophthalmic formulation
The decision comes as BioNTech has chosen not to participate further in the programme under the existing collaboration agreement. Despite this change, Genmab will still be required to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.